Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions of Daxors BVA-100 Blood Volume Analyzer slated for Q3 2021
Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions of Daxors BVA-100 Blood Volume Analyzer slated for Q3 2021